approval
saveKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
community read0 votes
Sponsor: GENENTECH. Form: VIAL. Route: SINGLE-USE
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalMar 26, 2026 · 190d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalMay 14, 2025 · 506d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalFeb 2, 2022 · 1703d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalSep 27, 2020 · 2196d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalDec 18, 2018 · 2845d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalSep 20, 2018 · 2934d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalJul 25, 2016 · 3721d ago
- approvalKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalApr 28, 2016 · 3809d ago
same company · ±60 days · 6
- approvalatezolizumab: TECENTRIQ (ATEZOLIZUMAB) — FDA approvalMay 6, 2019
- approvalatezolizumab: TECENTRIQ (ATEZOLIZUMAB) — FDA approvalMay 6, 2019
- approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalApr 11, 2019
- approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalApr 11, 2019
- approvaltocilizumab: ACTEMRA (TOCILIZUMAB) — FDA approvalApr 11, 2019
- approvalpolatuzumab vedotin: POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approvalJun 10, 2019
comments(0)
5-min edit window · permanent after that